210 related articles for article (PubMed ID: 6324326)
21. [Correlation between hemorheological and blood coagulation parameters in patients with arteriosclerosis of supraaortic vessels and/or recent cerebral ischemic attacks].
Avellone G; Di Garbo V; Cordova R; Alletto G; Abruzzese G; Strano A
Ric Clin Lab; 1989; 19 Suppl 1():103-7. PubMed ID: 2629066
[No Abstract] [Full Text] [Related]
22. [Hemorrheological anomalies: an element of additional risk in arterial diseases].
Mancini M; Postiglione A; Lamenza F; Patti L; Rubba P
Ric Clin Lab; 1983; 13 Suppl 3():181-8. PubMed ID: 6672994
[TBL] [Abstract][Full Text] [Related]
23. [Clinical value of hemorrheology in peripheral arterial occlusive diseases].
Sciannameo F; Francucci M; Cao PG; Giustozzi G; Valentini M; Tockner M; Sassano L; Grasselli A
Ric Clin Lab; 1983; 13 Suppl 3():417-22. PubMed ID: 6673023
[TBL] [Abstract][Full Text] [Related]
24. [Regional hemorheological effects induced by muscular exertion in peripheral obstructive arteriopathy. II].
Perego MA; Sergio G; Espureo M; Giunti P; Francisci A; La Penna F; Artale F
Minerva Cardioangiol; 1981; 29(7-8):375-82. PubMed ID: 7279238
[No Abstract] [Full Text] [Related]
25. [Hemorheologic and blood coagulation studies in 94 patients with chronic obstructive peripheral arterial disease].
Bracale G; Selvetella L; Bernardo B; Scalise E; Bertone L; De Caterina M
Ric Clin Lab; 1985; 15 Suppl 1():195-203. PubMed ID: 3929368
[TBL] [Abstract][Full Text] [Related]
26. [Hemorrheological determinants and metabolic parameters in reactive hypertension caused by exertion].
Caimi G; Assennato P; Capobianco D; Raineri A; Sarno A
Ric Clin Lab; 1983; 13 Suppl 3():395-9. PubMed ID: 6673019
[TBL] [Abstract][Full Text] [Related]
27. [The influence of hemorrheology on the practice of clinical medicine].
Dormandy JA
Ric Clin Lab; 1983; 13 Suppl 3():7-27. PubMed ID: 6369497
[TBL] [Abstract][Full Text] [Related]
28. [Hemorrheological changes in ischemic heart disease].
Forconi S; Guerrini M; Pieragalli D; Acciavatti A; Del Bigo C; Galigani C; Di Perri T
Ric Clin Lab; 1983; 13 Suppl 3():195-208. PubMed ID: 6672996
[TBL] [Abstract][Full Text] [Related]
29. Ozonized autohemotransfusion improves hemorheological parameters and oxygen delivery to tissues in patients with peripheral occlusive arterial disease.
Giunta R; Coppola A; Luongo C; Sammartino A; Guastafierro S; Grassia A; Giunta L; Mascolo L; Tirelli A; Coppola L
Ann Hematol; 2001 Dec; 80(12):745-8. PubMed ID: 11797116
[TBL] [Abstract][Full Text] [Related]
30. [Suloctidil (sulocton) in the treatment of atherosclerotic neurasthenic syndromes].
Prusiński A; Kotwica S; Niewodniczy A; Split W
Wiad Lek; 1982 May; 35(3-4):201-5. PubMed ID: 6287740
[No Abstract] [Full Text] [Related]
31. Discriminatory function of hemorheological variables in peripheral arterial disease.
Ernst E; Matrai A
Vasa; 1988; 17(2):98-101. PubMed ID: 3407320
[No Abstract] [Full Text] [Related]
32. [Behavior of various blood coagulation and hemorrheological parameters in arteriosclerotic vascular disease of the lower legs].
Avellone G; Mandalà V; Novo S; Pinto A; Davì G; Raneli G; Strano A
Ric Clin Lab; 1983; 13 Suppl 3():297-301. PubMed ID: 6200915
[TBL] [Abstract][Full Text] [Related]
33. [Hemorrheological changes in peripheral obliterative arterial diseases].
Bartoli V; Albanese B; Morini R; Pasquini G; Manescalchi PG
Ric Clin Lab; 1983; 13 Suppl 3():209-18. PubMed ID: 6672997
[TBL] [Abstract][Full Text] [Related]
34. [Role of the blood platelets in the atherosclerotic process and clinical use of a new drug, Suloctidil, with anti-aggregating activity].
Armani U; Piana A
Arch Maragliano Patol Clin; 1979; 35(2):57-62. PubMed ID: 233645
[No Abstract] [Full Text] [Related]
35. Clinical and biological activity of the antiplatelet agent suloctidil in treatment of idiopathic recurrent vein thrombosis (I.R.V.T.).
Moriau M; Col-De Beys C; Pardonge E; Ferrant A
Thromb Haemost; 1982 Feb; 47(1):27-31. PubMed ID: 6280332
[TBL] [Abstract][Full Text] [Related]
36. Factors influencing in vitro sieving of blood in cerebrovascular accidents. Clinical significance and therapeutic strategy.
Boisseau MR; Freyburger G; Lorient-Roudaut MF
Klin Wochenschr; 1986 Oct; 64(20):1053-7. PubMed ID: 3784456
[TBL] [Abstract][Full Text] [Related]
37. [Heparin-induced extracorporeal LDL precipitation (HELP): a new therapeutic intervention in cerebrovascular diseases and peripheral arterial occlusive disease].
Walzl B; Walzl M; Lechner P; Lechner H; Cesnik H
Wien Med Wochenschr; 1993; 143(22):563-70. PubMed ID: 8154130
[TBL] [Abstract][Full Text] [Related]
38. [Hemorheological aspects in relation to age and to the presence of arteriosclerotic disease].
Neirotti M; Molaschi M; Pernigotti L; Milla A; Fabris F
Ric Clin Lab; 1989; 19 Suppl 1():69-74. PubMed ID: 2629090
[No Abstract] [Full Text] [Related]
39. [Therapy of chronic peripheral arterial occlusive diseases with snake venom enzyme Arwin].
Ehrly AM
Med Welt; 1975 Mar; 26(10):446-55. PubMed ID: 1123988
[No Abstract] [Full Text] [Related]
40. Controlled trial of suloctidil in intermittent claudication.
Verhaeghe R; Van Hoof A; Beyens G
J Cardiovasc Pharmacol; 1981; 3(2):279-86. PubMed ID: 6166799
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
